The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJudges Scientific Regulatory News (JDG)

Share Price Information for Judges Scientific (JDG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10,975.00
Bid: 10,850.00
Ask: 11,100.00
Change: 0.00 (0.00%)
Spread: 250.00 (2.304%)
Open: 10,900.00
High: 10,900.00
Low: 10,900.00
Prev. Close: 10,900.00
JDG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

22 Sep 2020 07:00

RNS Number : 6383Z
Judges Scientific PLC
22 September 2020
 

Judges Scientific plc

("Judges Scientific", "the Company", or "the Group")

Interim results for the six months ended 30 June 2020

 

Resilient profitability and cash generation throughout despite impact of COVID-19.

Further execution of the Group's buy and build model with the Heath Scientific acquisition.

10% increase to interim dividend.

 

 

Judges Scientific, the group focused on acquiring and developing companies in the scientific instrument sector, announces its Interim Results for the six months ended 30 June 2020.

Key financials

Period ended 30 June

H1 2020

H1 2019

Change

Revenue

£37.4m

£40.2m

(6.8%)

Adjusted* pre-tax profit

£6.4m

£8.4m

(22.3%)

Adjusted* basic earnings per share

84.2p

108.7p

(22.5%)

Cash generated from operations

£5.1m

£8.5m

(40.0%)

Interim dividend per share

16.5p

15.0p

10.0%

Statutory pre-tax profit

£4.3m

£6.9m

(37.4%)

Statutory basic earnings per share

57.8p

90.1p

(35.8%)

As at:

30 Jun 2020

31 Dec 2019

Adjusted* net debt (excl. IFRS 16)

£6.4m

£2.0m

Cash balances

£19.4m

£14.1m

Statutory net debt (excl. IFRS 16)

£3.9m

£0.3m

Other financials

· Organic** revenue reduced 12% against H1 2019 as a result of Covid-19 impact in the period.

· Organic** order intake down 17% compared with H1 2019.

· Organic** order book at 10.8 weeks (H1 2019: 13.2 weeks); total order book at 12.4 weeks.

Acquisition 

· Heath Scientific was acquired on 29 May 2020 for £7.3 million plus excess cash.

Outlook

· Our markets still remain uncertain, with the expectation that research funding and university financing throughout the world may take time to recover.

· The Board believes that many of the orders that were not obtained have been deferred rather than cancelled.

· H2 Organic orders to 18 September are 13.8% down compared to the same period in 2019; year-to date Organic orders now 16.2% down.

· Total order book at the end of August was 13.2 weeks.

· Cautious confidence in the ability of the Group to meet existing market expectations for the year.

* Adjusted earnings figures are stated before adjusting items relating to hedging of risks materialising after the end of the period, amortisation of acquired intangible assets, share based payments and acquisition-related costs. Adjusted net debt notionally includes acquisition-related payments which had yet to be settled at the balance sheet date and excludes subordinated debt owed by subsidiaries to non-controlling shareholders and excludes IFRS 16 debt.

** Organic designates group performance excluding the businesses which were not part of the group on 1 January 2019.

 

Alex Hambro, Chairman of Judges Scientific, commented:

"The Group's performance was impacted by the outbreak of COVID-19 and the subsequent difficult trading conditions associated with lockdowns across the globe. Despite this, the Group's business model has remained intact with the Company continuing to be profitable and cash generative throughout the period and executing on its acquisition strategy. This has been possible thanks to the ongoing efforts of our colleagues at all levels. I would like to thank them for their hard work in these challenging times.

"Whilst uncertainty does remain, the Board's belief in the long-term fundamentals of the Group remain unchanged, with its robust business model and its exposure to long-term secular growth drivers."

 For further information please contact:

Judges Scientific plc

 Tel: +44 (0) 20 3829 6970

David Cicurel, CEO

Brad Ormsby, Group FD

Shore Capital (Nominated Adviser & Joint Broker)

Stephane Auton

Edward Mansfield

Sarah Mather

Tel: +44 (0) 20 7408 4090

 

Liberum (Joint Broker)

Bidhi Bhoma

Euan Brown

 

Alma (Financial Public Relations)

Rebecca Sanders-Hewett

Sam Modlin

 

Tel: +44 (0) 20 3100 2222

 

 

 

Tel: +44 (0) 20 3405 0205

Chairman's statement

 

The outbreak of the coronavirus, with the consequential lockdowns in most of our markets, has had a material impact on the Group's trading performance, particularly on order intake which fundamentally drives all other Group key performance metrics.

The challenges that our teams have faced have been substantial. I would like to take this opportunity to thank them all for the way they have responded, particularly in adapting to the new ways of working.

Despite the difficult environment created by the COVID-19 pandemic, the Group was able to complete the acquisition of Heath Scientific Company Limited ("Heath" or "THT") in May demonstrating the resilience of our business model.

The Group's results for the period include six-months trading from Moorfield Nanotechnology and one month from Heath; information excluding the contribution from these recently acquired businesses is shown as "Organic".

COVID-19

Since the emergence of COVID-19 as a pandemic, the main priority for the Group has been to ensure the safety of our colleagues through adherence to the UK government's rules and guidelines around social distancing and hygiene, and approximately half of our staff continue to work from home. Thanks to the Group's decentralised structure, our businesses have been able to put in place highly tailored and specific solutions to allow manufacturing to continue throughout the crisis. Thanks also to the efforts of our colleagues at all levels, to date none of our employees have been seriously ill and none of our facilities have been contaminated.

The Group has only suffered minor supply chain issues, all of which have been mitigated and managed accordingly. Customer closures have resulted in a minority of deliveries being postponed and many installations have still to be performed.

As outlined in our previous COVID-19 trading updates, the Board implemented a range of measures to control costs and preserve cash. As a result of those actions, we continue to be in a healthy and secure financial position, and the Group has remained profitable and cash generative throughout the period.

The Group's current intention is to use the return-to-work bonus scheme introduced by the Government to part-compensate staff whose remuneration was impacted or who suffered hardship as a result of the Group's compliance with the Government's measures to fight COVID.

Order intake

Across the Group, Organic order intake as of 30 June 2020 was down 17% compared to the same period in 2019. This was caused by the closure of universities, the cancellation of scientific conferences and our inability to travel, as well as capital expenditure freezes by industrial customers. This contraction in order intake was not evenly spread across our key geographies, with the UK decreasing 5%, China/Hong Kong and the Rest of Europe each down 7%; North America down 32% and the Rest of the World down 24%. Order intake also varied considerably from business to business. The downturn was most brutal in April when Organic intake was reduced to 40% of normal levels. Organic intake recovered in May to recoup nearly half of the deficit, and continued to recover in June.

Efforts to sustain revenues resulted in a partial consumption of the order book; the Organic order book as at 30 June 2020 was eroded from the 13.2 weeks available at the beginning of the period to 10.8 weeks of budgeted revenue, which in the Board's view is still satisfactory. Total order book stood at 12.4 weeks.

Revenues

Group revenues for the period decreased to £37.4 million (H1 2019: £40.2 million). This comprised a 12% reduction in Organic revenues, partially offset by the contribution of newly acquired businesses. Organic revenue contracted less than Organic order intake as a result of the compression of the Organic order book from the healthy opening level. Whilst order weakness was the main driver of the revenue slowdown, the inability of our customers to receive deliveries delayed a number of sales but this was alleviated toward the end of the period.

Organic sales were strong in China/Hong Kong (up 30%) and the UK (up 8%) but were particularly weak in North America (down 30%). The rest of Europe receded by 14% and the Rest of the World by 7%.

Profits

The reduced revenues have had a significant impact on profitability reflecting the operational gearing within the Group. Without proactive management, a 12% reduction in Organic revenue would ordinarily have negatively impacted operating profit by a third. This was partially offset by natural savings (travel, scientific conferences and bonuses), by the deferral of budgeted projects and by reductions in personnel costs; the impact of which were largely softened by the UK Government's Coronavirus Job Retention Scheme. This resulted in adjusted operating profit decreasing 22% to £6.7 million (H1 2019: £8.6 million) and adjusted pre-tax profit decreasing 24% to £6.4 million (H1 2019: £8.4 million).

Return on Total Invested Capital ("ROTIC") remained strong albeit receding to 26.6% for the trailing 12 months ended 30 June 2020 (31 December 2019: 31.4%; 30 June 2019: 31.0%).

Adjusted basic earnings per share reduced 23% to 84.2p (H1 2019: 108.7p) and adjusted diluted earnings per share reduced similarly from 107.0p to 82.5p.

Your Directors continue to show adjusted figures, prepared consistently with past reports, in order to communicate to shareholders what is, in the Directors' opinion, the true operating performance of the Group. The total adjustments of £2.1 million (H1 2019: £1.5 million) consist primarily of a £1.4 million charge for amortisation of acquired intangible assets arising through acquisition. The main movement from H1 2019 is the acquisition costs in respect of Heath. The adjusting items reduce profit before tax from £6.4 million to £4.3 million (H1 2019: £6.9 million) and earnings per share to 57.8p basic and 56.6p diluted (H1 2019: 90.1p basic and 88.6p diluted).

Cashflow and net debt

Cash flow during the first half of 2020 mirrored the trading challenges, with cash generated from operations of £5.1 million (H1 2019: £8.5 million) representing 76% of adjusted operating profit (H1 2019: 98%). Cash conversion was affected by increased working capital requirements from stockpiling of components to counteract potential supply channel difficulties; by the inability of customers to receive shipments and by payment delays due to our inability to travel and perform installations. The interim balance sheet includes cash balances of £19.4 million and adjusted net debt of £6.4 million, from £2.0 million at the beginning of 2020. To secure our position at the outset of the lockdown, Lloyds Bank agreed to repurpose £5 million of our revolving credit facility; this was drawn down in full and has contributed to the healthy cash balance.

Acquisitions

In line with the Group's buy and build model, the Group acquired Heath on 29 May 2020 for a total cash consideration of £7.3 million, including a £2.0 million earn-out which was paid in full after the end of the period, together with an amount equal to the excess cash not required in the business. The Bletchley-based business makes calorimetry instruments used to measure heat release during chemical reactions; the main application is ensuring the safety of Lithium-ion batteries and the main market is China. In the twelve-month period to 30 April 2020, Heath produced adjusted EBIT of £1.3 million.

On 31 March 2020, the Group purchased the outstanding shares (25.5% of the issued share capital) it did not previously own in PE Fiberoptics for a cash consideration of £1.1 million.

Dividend

In accordance with the Company's policy of increasing dividends by no less than 10% per annum, and bearing in mind the generous dividend cover and the fact that shareholders are also stakeholders, the Board is declaring an interim dividend of 16.5p (2019: 15.0p), which will be paid on Friday 6 November 2020 to shareholders on the register on Friday 9 October 2020. The shares will go ex-dividend on Thursday 8 October 2020. The interim dividend is covered 5 times by adjusted earnings (2019: 7 times).

Board change

We are delighted that Lushani Kodituwakku will be joining the Board on 23 September 2020 as an independent Non-Executive Director and will also be a member of the Remuneration Committee. Lushani is the founder and CEO of Luminii Consulting, a consulting firm specialising in strategy, Commercial Due Diligence ("CDD") and value creation. Lushani holds a Bachelor of Science (BSc) in Economics with first-class honours, and a Master of Research (MRes) in Management and Organisational Behaviour.

Lushani brings extensive expertise in strategy, CDD and value creation. We look forward to her guidance over the coming years as the Group continues to execute its buy and build growth strategy. 

Outlook

The Group is fortunate that it is operating in a relatively sheltered sector and the Directors believe that many of the orders that were not obtained during the period have been deferred rather than cancelled. However, great uncertainty persists on the timing of a return to normal due to the threat of further outbreaks across the globe. In addition, research funding and university financing throughout the world may be affected even after the health emergency has subsided.

H2 Organic orders to 18 September are 13.8% down compared to the same period in 2019 bringing the year-to date Organic orders to 16.2% down. The total order book at the end of August was 13.2 weeks, and this provides the board with cautious confidence in the ability of the Group to meet the existing market expectations for the year as a whole.

Throughout this difficult period the Group has proven its resilience; its ability to operate its businesses profitably and to execute its acquisition strategy should provide shareholders with confidence that the long-term prospects of the Group are unaffected.

 

The Hon. Alexander Hambro

Chairman

21 September 2020

 

 

Condensed consolidated interim statement of comprehensive income

 

Note

Adjusted

£000

Adjusting

 items

£000

Six months to

30 June

2020

£000

Six months

 to

30 June

2019

£000

Year to

 31 December

2019

£000

Revenue

3

37,449

-

37,449

40,169

82,499

Operating costs

(30,746)

-

(30,746)

(31,539)

(65,115)

Adjusted operating profit

3

6,703

-

6,703

8,630

17,384

Adjusting items

4

-

(2,080)

(2,080)

(1,480)

(3,274)

Operating profit/(loss)

6,703

(2,080)

4,623

7,150

14,110

Interest income

13

-

13

49

101

Interest expense

4

(281)

(22)

(303)

(282)

(580)

Profit/(loss) before tax

6,435

(2,102)

4,333

6,917

13,631

Taxation (charge)/credit

(940)

363

(577)

(1,051)

(1,777)

Profit/(loss) for the period

5,495

(1,739)

3,756

5,866

11,854

Attributable to:

Owners of the parent

5,268

(1,654)

3,614

5,592

11,382

Non-controlling interests

227

(85)

142

274

472

Profit/(loss) for the period

5,495

(1,739)

3,756

5,866

11,854

Other comprehensive income

Items that will not be reclassified subsequently to profit or loss

Retirement benefits loss

(740)

(250)

(375)

Items that may be reclassified subsequently to profit or loss

Exchange differences on translation of foreign subsidiaries

144

16

(62)

Other comprehensive expense for the period, net of tax

(596)

(234)

(437)

Total comprehensive income for the period

3,160

5,632

11,417

Attributable to:

Owners of the parent

3,018

5,358

10,945

Non-controlling interests

142

274

472

 

Pence

Pence

Pence

Earnings per share - adjusted

Basic

5

84.2

108.7

222.5

Diluted

5

82.5

107.0

218.4

Earnings per share - total

Basic

5

57.8

90.1

183.1

Diluted

5

56.6

88.6

179.8

 

 

Condensed consolidated interim balance sheet

 

Note

30 June

2020

£000

30 June

2019

£000

31 December

2019

£000

ASSETS

Non-current assets

Goodwill

18,196

14,650

15,265

Other intangible assets

6

7,098

3,989

4,458

Property, plant and equipment

6,583

5,460

6,107

Right-of-use leased assets

4,295

2,610

4,428

Deferred tax assets

2,131

775

1,873

38,303

27,484

32,131

Current assets

Inventories

14,040

11,926

12,543

Trade and other receivables

12,666

11,610

11,814

Cash and cash equivalents

19,422

20,780

14,123

46,128

44,316

38,480

Total assets

84,431

71,800

70,611

LIABILITIES

Current liabilities

Trade and other payables

(15,069)

(12,988)

(15,322)

Trade and other payables relating to acquisitions

(2,769)

-

(1,896)

Borrowings

(3,047)

(3,047)

(3,051)

Right-of-use lease liabilities

(854)

(650)

(757)

Current tax liabilities

(2,512)

(2,572)

(2,258)

(24,251)

(19,257)

(23,284)

Non-current liabilities

Borrowings

(20,244)

(10,541)

(11,399)

Right-of-use lease liabilities

(3,468)

(1,900)

(3,689)

Deferred tax liabilities

(1,819)

(1,215)

(1,447)

Retirement benefit obligations

10

(3,088)

(2,162)

(2,100)

(28,619)

(15,818)

(18,635)

Total liabilities

(52,870)

(35,075)

(41,919)

Net assets

31,561

36,725

28,692

EQUITY

Share capital

7

314

311

311

Share premium

16,068

15,359

15,453

Other reserves

2,203

2,137

2,059

Retained earnings

12,404

18,295

10,048

Equity attributable to owners of the parent

30,989

36,102

27,871

Non-controlling interests

572

623

821

Total equity

31,561

36,725

28,692

 

 

Condensed consolidated interim statement of changes in equity

 

Share

capital

£000

Share

premium

£000

Other

reserves

£000

Retained

earnings

£000

Total attributable

to owners

of parent

£000

Non-

controlling

interests

£000

Total

equity

£000

At 1 January 2020

311

15,453

2,059

10,048

27,871

821

28,692

Adjustment arising from change in non-controlling interest

-

-

-

(680)

(680)

(391)

(1,071)

Issue of share capital

3

615

-

-

618

-

618

Share-based payments

-

-

-

162

162

-

162

Transactions with owners

3

615

-

(518)

100

(391)

(291)

Profit for the period

-

-

-

3,614

3,614

142

3,756

Retirement benefit actuarial loss

-

-

-

(740)

(740)

-

(740)

Foreign exchange differences

-

-

144

-

144

-

144

Total comprehensive income for the period

-

-

144

2,874

3,018

142

3,160

At 30 June 2020

314

16,068

2,203

12,404

30,989

572

31,561

 

Share

capital

£000

Share

premium

£000

Other

reserves

£000

Retained

earnings

£000

Total attributable

to owners

of parent

£000

Non-

controlling

interests

£000

Total

equity

£000

At 1 January 2019

310

15,164

2,121

13,049

30,644

562

31,206

Adjustment arising from change in non-controlling interest

-

-

-

(204)

(204)

(213)

(417)

Issue of share capital

1

195

-

-

196

-

196

Share-based payments

-

-

-

108

108

-

108

Transactions with owners

1

195

-

(96)

100

(213)

(113)

Profit for the period

-

-

-

5,592

5,592

274

5,866

Retirement benefit actuarial loss

-

-

-

(250)

(250)

-

(250)

Foreign exchange differences

-

-

16

-

16

-

16

Total comprehensive income for the period

-

-

16

5,342

5,358

274

5,632

At 30 June 2019

311

15,359

2,137

18,295

36,102

623

36,725

 

Share

capital

£000

Share

premium

£000

Other

reserves

£000

Retained

earnings

£000

Total attributable

to owners

of parent

£000

Non-

controlling

interests

£000

Total

equity

£000

At 1 January 2019

310

15,164

2,121

13,049

30,644

562

31,206

Dividends

-

-

-

(15,126)

(15,126)

-

(15,126)

Adjustment arising from change in non-controlling interest

-

-

-

(204)

(204)

(213)

(417)

Issue of share capital

1

289

-

-

290

-

290

Deferred tax on share-based payments

-

-

-

1,027

1,027

-

1,027

Share-based payments

-

-

-

295

295

-

295

Transactions with owners

1

289

-

(14,008)

(13,718)

(213)

(13,931)

Profit for the year

-

-

-

11,382

11,382

472

11,854

Retirement benefit actuarial loss

-

-

-

(375)

(375)

-

(375)

Foreign exchange differences

-

-

(62)

-

(62)

-

(62)

Total comprehensive income for the year

-

-

(62)

11,007

10,945

472

11,417

At 31 December 2019

311

15,453

2,059

10,048

27,871

821

28,692

 

 

Condensed consolidated interim cashflow statement

 

Six months to

30 June

2020

£000

Six months to

30 June

2019

£000

Year to

31

December

2019

£000

Cashflows from operating activities

Profit after tax

3,756

5,866

11,854

Adjustments for:

Financial instruments measured at fair value: hedging contracts

146

(12)

(37)

Share-based payments

162

108

295

Depreciation of property, plant and equipment

431

367

771

Depreciation of right-of-use leased assets

436

395

863

Amortisation of intangible assets

1,360

1,384

2,739

(Profit)/loss on disposal of property, plant and equipment

(3)

(28)

1

Charge on exit from right-of-use leases

-

-

39

Interest income

(13)

(49)

(101)

Interest expense

196

212

397

Retirement benefit obligation net interest cost

22

25

48

Interest payable on right-of-use lease liabilities

85

45

135

Contributions to defined benefit plans

-

-

(236)

Tax recognised in the Statement of Comprehensive Income

577

1,051

1,777

Increase in inventories

(716)

(1,424)

(1,794)

(Increase)/decrease in trade and other receivables

(39)

1,486

1,566

(Decrease)/increase in trade and other payables

(1,296)

(937)

763

Cash generated from operations

5,104

8,489

19,080

Tax paid

(749)

(947)

(2,205)

Net cash from operating activities

4,355

7,542

16,875

Cashflows from investing activities

Paid on acquisition of subsidiaries

(5,274)

-

(2,288)

Payment of deferred consideration

(1,896)

-

-

Gross cash inherited on acquisition

969

-

2,201

Acquisition of subsidiaries, net of cash acquired

(6,201)

-

(87)

Purchase of property, plant and equipment

(675)

(314)

(1,303)

Proceeds from the sale of property, plant and equipment

3

28

22

Interest received

13

49

101

Net cash used in investing activities

(6,860)

(237)

(1,267)

Cashflows from financing activities

Proceeds from issue of share capital

618

196

290

Finance costs paid

(200)

(210)

(393)

Repayments of borrowings

(1,429)

(1,440)

(2,868)

Repayments of right-of-use lease liabilities

(527)

(408)

(926)

Proceeds from bank loans

10,274

-

2,288

Equity dividends paid

-

-

(15,126)

Paid on acquisition of non-controlling interest in subsidiary

(1,071)

(417)

(417)

Net cash from/(used in) financing activities

7,665

(2,279)

(17,152)

Net change in cash and cash equivalents

5,160

5,026

(1,544)

Cash and cash equivalents at start of period

14,123

15,727

15,727

Exchange movements

139

27

(60)

Cash and cash equivalents at end of period

19,422

20,780

14,123

 

 

 

Notes to the interim report

 

1. General information and basis of preparation

The Judges Scientific plc Group's principal activities comprise the design, manufacture and sale of scientific instruments. The subsidiaries are grouped into two segments: Materials Sciences and Vacuum.

The financial information set out in this Interim Report for the six months ended 30 June 2020 and the comparative figures for the six months ended 30 June 2019 are unaudited. The Interim Report has been prepared in accordance with IAS 34 'Interim Financial Reporting'. The Interim Report does not contain all the information required for full annual financial statements and should be read in conjunction with the consolidated financial statements of the Group for the year ended 31 December 2019, which have been prepared in accordance with IFRS as adopted by the European Union.

The financial information for the year ended 31 December 2019 set out in this Interim Report does not constitute statutory accounts as defined in section 434 of the Companies Act 2006. The Group's statutory financial statements for the year ended 31 December 2019 have been filed with the Registrar of Companies. The Auditor's Report in respect of those financial statements was unqualified and did not contain statements under section 498 of the Companies Act 2006.

Judges Scientific plc is the Group's ultimate parent company. The Company is a public limited company incorporated and domiciled in the United Kingdom. Its registered office and principal place of business is 52c Borough High Street, London SE1 1XN and the Company's shares are quoted on the Alternative Investment Market. The Interim Report is presented in Sterling, which is the functional currency of the parent company. The Interim Report has been approved for issue by the Board of Directors on 21 September 2020.

Going concern

The consolidated financial statements have been prepared on a going concern basis. The Group ended the first half of 2020 with adjusted net debt of £6.4 million (equal to 19% of equity) compared to adjusted net debt of £2.0 million at 31 December 2019. This arose through profitable and cash generative trading of the Group's principal operating companies throughout the first half of 2020, offset by the continued execution of the Group's buy and build strategy where we acquired Thermal Hazard Technology Limited for £7.3 million, and £1.0 million was allocated to increasing the Group's shareholding in one of its majority-owned businesses.

The Directors have considered the impact of the COVID-19 pandemic, and a summary of the implications is included in the Chairman's Statement. Our financial position remains robust, with high cash balances and low gearing together with a satisfactory order book. The Directors have also performed reasonably possible stress testing on forecast cash flows, considering potential scenarios from the pandemic and, as a result, consider that the Group is appropriately placed to manage its business risks.

The Directors therefore have a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future. Therefore, they continue to adopt the going concern basis in preparing the Interim Report.

2. Significant accounting policies

The Interim Report has been prepared in accordance with the accounting policies adopted in the last annual financial statements for the year ended 31 December 2019, except for the taxation policy where, for the purposes of the interim results, the tax charge on adjusted business performance is calculated by reference to the estimated effective rate for the full year.

Additionally, the Statement of Comprehensive Income includes government grants, which are accounted for in line with IAS 20. Income is recognised in the Statement of Comprehensive Income over the same period as the costs to which the grants relate, and is only recognised once there is reasonable assurance that the Group has complied with the conditions of the grant and that the grant will be received.

3. Segmental analysis

For the period ended 30 June 2020

Note

Materials

Sciences

£000

Vacuum

£000

Unallocated

items

£000

Total

£000

Revenue

14,675

22,774

-

37,449

Operating costs

(12,274)

(17,110)

(1,362)

(30,746)

Adjusted operating profit

2,401

5,664

(1,362)

6,703

Adjusting items

4

(2,080)

Operating profit

4,623

Net interest expense

(290)

Profit before tax

4,333

Income tax charge

(577)

Profit for the period

3,756

 

For the period ended 30 June 2019

Note

Materials

Sciences

£000

Vacuum

£000

Unallocated

items

£000

Total

£000

Revenue

15,929

24,240

-

40,169

Operating costs

(12,702)

(17,566)

(1,271)

(31,539)

Adjusted operating profit

3,227

6,674

(1,271)

8,630

Adjusting items

4

(1,480)

Operating profit

7,150

Net interest expense

(233)

Profit before tax

6,917

Income tax charge

(1,051)

Profit for the period

5,866

 

For the year ended 31 December 2019

Note

Materials

Sciences

£000

Vacuum

£000

Unallocated

items

£000

Total

£000

Revenue

34,819

47,680

-

82,499

Operating costs

(27,169)

(35,569)

(2,377)

(65,115)

Adjusted operating profit

7,650

12,111

(2,377)

17,384

Adjusting items

4

(3,274)

Operating profit

14,110

Net interest expense

(479)

Profit before tax

13,631

Income tax charge

(1,777)

Profit for the year

11,854

Unallocated items relate to the Group's head office costs.

Segment assets and liabilities

At 30 June 2020

Materials

Sciences

£000

Vacuum

£000

Unallocated

items

£000

Total

£000

Assets

24,155

30,222

30,054

84,431

Liabilities

(10,970)

(11,216)

(30,684)

(52,870)

Net assets

13,185

19,006

(630)

31,561

Capital expenditure

121

544

10

675

Depreciation of property, plant and equipment

113

295

23

431

Depreciation of right-of-use leased assets

203

205

28

436

Amortisation

392

968

-

1,360

 

At 30 June 2019

Materials

Sciences

£000

Vacuum

£000

Unallocated

items

£000

Total

£000

Assets

16,694

26,790

28,316

71,800

Liabilities

(8,077)

(13,366)

(13,632)

(35,075)

Net assets

8,617

13,424

14,684

36,725

Capital expenditure

78

224

12

314

Depreciation of property, plant and equipment

90

262

15

367

Depreciation of right-of-use leased assets

186

182

27

395

Amortisation

651

733

-

1,384

 

 

 

At 31 December 2019

Materials

Sciences

£000

Vacuum

£000

Unallocated

items

£000

Total

£000

Assets

20,392

30,351

19,868

70,611

Liabilities

(10,357)

(17,027)

(14,535)

(41,919)

Net assets

10,035

13,324

5,333

28,692

Capital expenditure

411

836

56

1,303

Depreciation of property, plant and equipment

189

552

30

771

Depreciation of right-of-use leased assets

410

399

54

863

Amortisation

1,209

1,530

-

2,739

Unallocated items are borrowings, intangible assets and goodwill arising on acquisition, deferred tax, defined benefit obligations and parent company net assets.

Geographic analysis

Six months to

30 June

2020

£000

Six months

 to

30 June

2019

£000

Year

to

31 December

2019

£000

UK (domicile)

5,153

4,539

9,690

Rest of Europe

10,847

11,780

23,418

North America

9,241

13,294

24,459

China/Hong Kong

5,286

3,648

9,487

Rest of the world

6,922

6,908

15,445

Revenue

37,449

40,169

82,499

4. Adjusting items

Six months to

30 June

2020

£000

Six months

 to

30 June

2019

£000

Year

 to

31 December

2019

£000

Amortisation of intangible assets

1,360

1,384

2,739

Financial instruments measured at fair value: hedging contracts

146

(12)

(37)

Share-based payments

162

108

295

Employment taxes arising from share-based payments

28

-

-

Acquisition costs

384

-

277

Total adjusting items within operating profit

2,080

1,480

3,274

Retirement benefits obligation net interest cost

22

25

48

Total adjusting items

2,102

1,505

3,322

Taxation

(363)

(265)

(707)

Total adjusting items net of tax

1,739

1,240

2,615

Attributable to:

Owners of the parent

1,654

1,158

2,446

Non-controlling interests

85

82

169

1,739

1,240

2,615

 

5. Earnings per share

Note

Six months to

30 June

2020

£000

Six months

 to

30 June

2019

£000

Year

 to

31 December

2019

£000

Profit for the period attributable to owners of the parent

Adjusted profit

5,268

6,750

13,828

Adjusting items

4

(1,654)

(1,158)

(2,446)

Profit for the period

3,614

5,592

11,382

 

Pence

Pence

Pence

Earnings per share - adjusted

Basic

84.2

108.7

222.5

Diluted

82.5

107.0

218.4

Earnings per share - total

Basic

57.8

90.1

183.1

Diluted

56.6

88.6

179.8

 

Number

Number

Number

Issued Ordinary shares at start of the period

7

6,226,291

6,196,678

6,196,678

Movement in Ordinary shares during the period

7

48,650

24,163

29,613

Issued Ordinary shares at end of the period

7

6,274,941

6,220,841

6,226,291

Weighted average number of shares in issue

6,254,512

6,207,925

6,215,817

Dilutive effect of share options

128,861

101,158

115,517

Weighted average shares in issue on a diluted basis

6,383,373

6,309,083

6,331,334

 

Adjusted basic earnings per share is calculated on the adjusted profit, which is presented before any adjusting items, attributable to the Company's shareholders divided by the weighted average number of shares in issue during the period.

Adjusted diluted earnings per share is calculated on the adjusted basic earnings per share, adjusted to allow for the issue of Ordinary shares on the assumed conversion of all dilutive options and any other dilutive potential Ordinary shares. The calculation is based on the treasury method prescribed in IAS 33. This calculates the theoretical number of shares that could be purchased at the average middle market price in the period out of the proceeds of the notional exercise of outstanding options. The difference between this theoretical number and the actual number of shares under option is deemed liable to be issued at nil value and represents the dilution.

Total earnings per share is calculated as above whilst substituting total profit for adjusted profit.

 

6. Other intangible assets

The following tables show the significant additions to and amortisation of intangible assets:

Carrying

amount at

1 January

2020

£000

Acquisition

£000

Amortisation

£000

Carrying

amount at

30 June

2020

£000

Acquired distribution agreements

400

-

(143)

257

Acquired technology

1,927

1,400

(474)

2,853

Acquired sales order backlog

119

400

(219)

300

Acquired brand and domain names

1,508

750

(372)

1,886

Acquired customer relationships

504

1,450

(152)

1,802

Total

4,458

4,000

(1,360)

7,098

 

 

 

Carrying

amount at

1 January

2019

£000

Acquisition

£000

Amortisation

£000

Carrying

amount at

30 June

2019

£000

Acquired distribution agreements

310

-

(110)

200

Acquired technology

2,458

-

(552)

1,906

Acquired brand and domain names

2,235

-

(512)

1,723

Acquired customer relationships

370

-

(210)

160

Total

5,373

-

(1,384)

3,989

 

Carrying

amount at

1 January

2019

£000

Acquisition

£000

Amortisation

£000

Carrying

amount at

31 December

2019

£000

Acquired distribution agreements

310

301

(211)

400

Acquired technology

2,458

583

(1,114)

1,927

Acquired sales order backlog

-

159

(40)

119

Acquired brand and domain names

2,235

302

(1,029)

1,508

Acquired customer relationships

370

479

(345)

504

Total

5,373

1,824

(2,739)

4,458

 

7. Share capital

Movements in the Group's Ordinary shares in issue are summarised as follows:

 

2020

£000

2019

£000

Allotted, called up and fully paid - Ordinary shares of 5p each

1 January: 6,226,291 shares (2019: 6,196,678 shares)

311

310

Exercise of share options: 48,650 shares (2019: 24,163 shares)

3

1

30 June: 6,274,941 shares (2019: 6,220,841 shares)

314

311

 

Allotments of Ordinary shares in the first six months of 2020 were made to satisfy the exercise of 48,650 share options in aggregate on 11 occasions during the year when the share price was within the range of 4300p to 5680p (2019: exercise of 24,163 share options when the share price was within the range 2660p to 3175p).

 

8. Changes in net debt

Changes in net debt for the six months ended 30 June 2020 were as follows:

1 January

2020

£000

Cashflow

£000

Non-cash

items

£000

30 June

2020

£000

Cash at bank and in hand

14,123

5,160

139

19,422

Bank debt

(14,260)

(8,841)

-

(23,101)

Net debt including senior debt

(137)

(3,681)

139

(3,679)

Subordinated debt to non-controlling shareholders

(190)

-

-

(190)

Total net debt

(327)

(3,681)

139

(3,869)

Subordinated debt to non-controlling shareholders

190

-

-

190

Accrued deferred consideration

(1,896)

(873)

-

(2,769)

Adjusted net debt

(2,033)

(4,554)

139

(6,448)

 

Non-cash items primarily represent foreign exchange differences on foreign currency bank balances.

 

The movement in borrowings over the period was as follows:

2020

£000

2019

£000

At 1 January

14,260

14,836

Proceeds from drawdown of loans

10,274

-

Repayment of loans

(1,429)

(1,440)

Interest payable

196

212

Interest paid

(200)

(210)

At 30 June

23,101

13,398

Subordinated debt to non-controlling shareholders

190

190

Total borrowings at 30 June

23,291

13,588

 

2020

£000

2019

£000

Current

3,047

3,047

Non-current

20,244

10,541

Total borrowings at 30 June

23,291

13,588

 

9. Acquisitions

On 29 May 2020 the Company acquired 100% of the issued share capital of Heath Scientific Company Limited, together with its wholly owned subsidiaries Thermal Hazard Technology Limited and THT Inc. ("THT"). THT is based in Bletchley, Buckinghamshire and specialises in the design and manufacture of scientific instruments focusing on calorimeters that are principally used to quantify thermal properties of lithium batteries as well as other reactive chemicals and materials.

The initial purchase price of THT, paid in cash at completion, amounted to £5.3 million. Additionally, an earn-out was payable based on THT's adjusted EBIT in the year to 30 April 2020, capped at £2.0 million, together with an amount to reflect any excess cash and working capital over and above the ongoing requirements of the business. The earn-out was achieved in full and the excess cash was covered by cash inherited at the completion date. Both amounts were paid in August 2020.

The summary provisional fair value of the cost of this acquisition includes the components stated below:

Consideration

£000

Initial cash consideration

5,274

Earn-out*

2,026

 

7,300

Gross cash inherited on acquisition

969

Cash retained in the business

(226)

Payment in respect of surplus working capital*

743

Total consideration

8,043

Acquisition-related transaction costs charged to the Statement of Comprehensive Income

384

*Paid in August 2020

The acquisition of THT was financed via drawdown from the Group's £35 million acquisition facility from Lloyds Bank Corporate Markets.

 

The summary provisional fair values recognised for the assets and liabilities acquired are as follows:

 

Book value

£000

Accounting policy alignments £000

Fair value

adjustments

£000

Fair value

£000

Intangible assets

-

-

4,000

4,000

Property, plant and equipment

263

(39)

-

224

Right-of-use leased assets

-

256

-

256

Deferred tax assets

-

-

121

121

Inventories

992

-

(211)

781

Trade and other receivables

1,126

-

(313)

813

Cash and cash equivalents

969

-

-

969

Total assets

3,350

217

3,597

7,164

Deferred tax liabilities

(27)

-

(760)

(787)

Trade payables

(788)

-

(111)

(899)

Right-of-use lease liabilities

-

(267)

-

(267)

Current tax liability

(99)

-

-

(99)

Total liabilities

(914)

(267)

(871)

(2,052)

Net identifiable assets and liabilities

2,436

(50)

2,726

5,112

Total consideration

8,043

Goodwill recognised

2,931

 

The intangible assets recognised reflect recognition of acquired customer relationships, the value of the acquired future committed order book, acquired technology together with brand and domain names. A significant amount of the value of the acquired business is attributable to its workforce and sales knowhow and contributes to the goodwill recognised upon acquisition. This goodwill has been allocated to the Materials Sciences segment.

The deferred tax liabilities recognised represent the tax effect which will result from the amortisation of the intangible assets, estimated using the tax rate substantively enacted at the balance sheet date and the fair value of the assets. Additional fair value adjustments include stock, doubtful debt, commission and warranty provisions together with any related deferred tax. Adjustments to property, plant and equipment and right-of-use assets and liabilities were made to align with Group accounting policies.

This acquisition resulted in a profit after tax (before adjusting items) attributable to owners of the parent company of £54,000 in the period post-acquisition. After amortisation of intangible assets, the contribution to owners of the parent company's results amounted to a loss of £89,000 after tax.

If the acquisition had completed on 1 January 2020, based on pro-forma results, revenue for the Group for the period ended 30 June 2020 would have increased by a further £2,100,000 and profit after tax (before adjusting items) attributable to the owners of the parent company would have increased by a further £360,000 after allowing for interest costs. Amortisation of intangible assets on a pro-forma basis from 1 January 2020 to the date of acquisition would have been £550,000.

Increased shareholding in PE.fiberoptics Limited

On 31 March 2020, Judges purchased the remaining 25.5% minority shareholding held in PE.fiberoptics Limited ("PFO") for a cash consideration of £1.07 million. As a result, Judges increased its ownership of the shares in PFO from 74.5% to 100%. The transaction was financed from Judges existing cash resources.

As this acquisition results in the entity becoming a wholly owned subsidiary, the purchase was accounted for by reducing the Non-Controlling Interest as at the date of the acquisition to £nil, and the remaining balance recorded through equity reserves.

10. Defined benefit scheme

The Group's defined benefit pension scheme liability has increased to £3.1 million compared to £2.1 million at 31 December 2019, due to a decrease of 0.5% in the discount rate to 1.6% from 2.1% at 31 December 2019, and an increase of 0.4% in the CPI inflation rate to 2.5% from 2.1% at 31 December 2019.

11. Dividends

During the period, the Company paid no dividends (period to 30 June 2019: £nil).

The Company paid a final dividend of 35.0p per share totalling £2.2 million to shareholders on 3 July 2020 relating to the financial year ended 31 December 2019 (28.0p per share totalling £1.7 million relating to the financial year ended 31 December 2018).

The Company will pay an interim dividend for 2020 of 16.5p per share (2019: interim dividend of 15.0p per share) on 6 November 2020 to shareholders on the register on 9 October 2020. The shares will go ex-dividend on 8 October 2020.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR QFLFLBKLFBBX
Date   Source Headline
16th Apr 20247:00 amRNSDirector/PDMR Shareholding
9th Apr 20245:29 pmRNSDirector/PDMR Shareholding
2nd Apr 202410:41 amRNSTotal Voting Rights - Correction
2nd Apr 20249:03 amRNSTotal Voting Rights
25th Mar 20246:01 pmRNSDirector/PDMR Shareholding
21st Mar 20247:00 amRNSFinal Results
7th Mar 20247:00 amRNSDirector/PDMR Shareholding
4th Mar 202411:04 amRNSTotal Voting Rights
22nd Feb 20245:20 pmRNSHolding(s) in Company
6th Feb 20243:03 pmRNSDirector/PDMR Shareholding
5th Feb 20249:32 amRNSTotal Voting Rights
1st Feb 20247:00 amRNSAcquisition of Luciol Instruments SA
24th Jan 20245:52 pmRNSGrant of Options
18th Jan 20247:00 amRNSFull Year Trading Statement and Notice of Results
8th Jan 20242:21 pmRNSDirector/PDMR Shareholding
2nd Jan 202410:49 amRNSTotal Voting Rights
21st Dec 20234:16 pmRNSDirector/PDMR Shareholding
21st Dec 20239:13 amRNSBlock listing Interim Review
7th Dec 202311:18 amRNSDirector/PDMR Shareholding
1st Dec 202311:20 amRNSTotal Voting Rights
22nd Nov 202310:41 amRNSDirector/PDMR Shareholding
21st Nov 20237:00 amRNSBoard Changes
15th Nov 202312:54 pmRNSDirector/PDMR Shareholding
9th Nov 202312:36 pmRNSDirector/PDMR Shareholding
9th Oct 202311:36 amRNSDirector/PDMR Shareholding
3rd Oct 202311:13 amRNSTotal Voting Rights
26th Sep 202310:37 amRNSDirector/PDMR Shareholding
20th Sep 20237:00 amRNSInterim Results
6th Sep 20237:00 amRNSNotice of Investor Presentation
2nd Aug 20233:02 pmRNSTotal Voting Rights
26th Jul 202311:20 amRNSDirector/PDMR Shareholding
18th Jul 20237:00 amRNSHalf Year Trading Update and Notice of Results
10th Jul 20233:03 pmRNSDirector/PDMR Shareholding
3rd Jul 20233:44 pmRNSTotal Voting Rights
22nd Jun 20233:09 pmRNSBlock listing Interim Review
14th Jun 20238:44 amRNSDirector/PDMR Shareholding
6th Jun 20238:45 amRNSPayment of Earn-out and Issue of Equity
5th Jun 20234:17 pmRNSDirector/PDMR Shareholding
1st Jun 20237:00 amRNSBlocklisting Application and Total Voting Rights
22nd May 20231:45 pmRNSResult of AGM
12th May 20232:01 pmRNSPurchase of Ordinary Shares
9th May 202312:37 pmRNSDirector/PDMR Shareholding
3rd May 20237:00 amRNSNotice of AGM
2nd May 20231:00 pmRNSTotal Voting Rights
2nd May 20237:00 amRNSAcquisition of Bossa Nova Vision LLC
25th Apr 20235:55 pmRNSDirector/PDMR Shareholding
6th Apr 20232:50 pmRNSDirector/PDMR Shareholding
4th Apr 202312:21 pmRNSTotal Voting Rights
3rd Apr 20237:01 amRNSAcquisition of Henniker Scientific Limited
3rd Apr 20237:00 amRNSAppointment of Joint Broker

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.